Evidence map›Paper›PMID 34954190›Full record

ArticleCellular and molecular gastroenterology and hepatology2022

Pharmacologic Antagonization of Cannabinoid Receptor 1 Improves Cholestasis in Abcb4

Nora Helmrich, Martin Roderfeld, Anne Baier, Anita Windhorst, Diran Herebian, Ertan Mayatepek, Christian Dierkes, Matthias Ocker, Dieter Glebe, Bruno Christ and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Interleukin13 Ameliorates Hepatocellular Steatosis via IL13Rα1/JNK/FOSL2 Signaling Pathway.Cellular and molecular gastroenterology and hepatology · 2026
    Article
  2. PNAS nexus · 2024
    Article
  3. Metabolic reprogramming of hepatocytes byJHEP reports : innovation in hepatology · 2023
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Nora HelmrichDepartment of Gastroenterology, Giessen, Germany.
Martin RoderfeldDepartment of Gastroenterology, Giessen, Germany.
Anne BaierDepartment of Gastroenterology, Giessen, Germany.
Anita WindhorstInstitute for Medical Informatics, Justus Liebig University, Giessen, Germany.
Diran HerebianDepartment of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital Duesseldorf, Heinrich Heine University, Duesseldorf, Germany.
Ertan MayatepekDepartment of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital Duesseldorf, Heinrich Heine University, Duesseldorf, Germany.
Christian DierkesMedizinisches Versorgungszentrum for Pathology, Justus Liebig University Giessen, Trier, Germany.
Matthias OckerInstitute for Surgical Research, Philipps University of Marburg, Marburg, Germany.
Dieter GlebeInstitute of Medical Virology, National Reference Centre for Hepatitis B Viruses and Hepatitis D Viruses, Justus Liebig University, Giessen, Germany.
Bruno ChristApplied Molecular Hepatology Laboratory, Department of Visceral, Transplant, Thoracic and Vascular Surgery, University of Leipzig Medical Center, Leipzig, Germany.
Yuri ChurinDepartment of Gastroenterology, Giessen, Germany.
Karuna IrungbamDepartment of Gastroenterology, Giessen, Germany.
Elke RoebDepartment of Gastroenterology, Giessen, Germany. Electronic address: Elke.Roeb@innere.med.uni-giessen.de.
Giessen School of Theology · DEUniversity of Giessen · DEDüsseldorf University Hospital · DEHeinrich Heine University Düsseldorf · DELeipzig University · DEPhilipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsThe endocannabinoid system is involved in the modulation of inflammatory, fibrotic, metabolic, and carcinogenesis-associated signaling pathways via cannabinoid receptor (CB)1 and CB2. We hypothesized that the pharmacologic antagonization of CB1 receptor improves cholestasis in Abcb4

methodsAfter weaning, male Abcb4

resultsCholestasis-induced symptoms such as liver damage, bile duct proliferation, and enhanced circulating bile acids were improved by CB1 antagonization. Rimonabant treatment also improved Phosphoenolpyruvat-Carboxykinase expression and reduced inflammation and the acute-phase response. The carcinogenesis-associated cellular-Jun N-terminal kinase/cellular-JUN and signal transducer and activator of transcription 3 signaling pathways activated in Abcb4

conclusionsWe showed a protective effect of oral CB1 antagonization in chronic cholestasis using the established Abcb4

Indexed as

CholestasisReceptor, Cannabinoid, CB1AnimalsCarcinogenesisInflammationMaleMiceRimonabantReceptor, Cannabinoid, CB1RimonabantAcute PhaseBile AcidFibrosisLiverRimonabant

Identifiers

PMID34954190
PMCPMC8873597
OpenAlexW4200570628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.